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| INTRODUCTION
Hemophilia A (HemA) is an X-linked recessive disorder due to factor VIII (FVIII) deficiency. HemA disease severity is defined by plasma FVIII levels, such that levels <1%, 1% to <5%, and 5% to <40% are classified as severe, moderate, and mild, respectively. 1 Currently, the standard of care in HemA is FVIII replacement, although non-replacement new therapies that bypass the need for FVIII are in development. [2] [3] [4] With FVIII therapy, the goal for HemA treatment is to elevate plasma FVIII levels to minimize time spent at low trough levels, although the optimal trough level to prevent bleeding is uncertain. [5] [6] [7] [8] Part of the uncertainty is related to variation in patient response to FVIII, likely due to the presence of disease modifiers. 9, 10 However, with nonfactor therapies, it is unclear whether targeting a specific FVIII equivalence would yield the desired result of effective clot formation, especially because these new therapeutics usually mediate their effects through mechanisms of action other than FVIII replacement. 2, 3 Therefore, it would be desirable to define what constitutes an effective clot, using FVIII replacement in HemA as a starting point, because the cofactor function of FVIII in coagulation is well understood. Additionally, because considerable variation exists in the response of HemA patients to therapy, it would be desirable to determine whether optimizing therapeutic dose (eg, restoring HemA plasma FVIII levels to 100%)
would eliminate variation in individual responses and generate optimal clots with homogeneous characteristics and properties.
In a mouse model for hemostasis, our results show that polyhedrocytes, formed as a consequence of clot contraction, and fibrin were major components of saphenous wound clots in wild-type (unaffected) mice with replete FVIII. In contrast, fibrin and polyhedrocytes formed much smaller fractions in HemA mice. The lower fibrin content in HemA clots was not unexpected, although the difference in polyhedrocyte content between HemA and unaffected mouse clots was unexpected and would be consistent with the altered permeability and stability of the clots, functions attributed to polyhedrocytes. 11 Because factors in addition to FVIII regulate coagulation, a more precise determinant of adequate treatment in patients with HemA may be an individual's capacity to form clots with adequate structural and viscoelastic properties, rather than absolute plasma FVIII levels. Correlation of individual HemA patient capacity to form clots with specific structures and properties when treated with different therapies may provide a basis for more effective treatment (ie, minimizing bleeding frequency) while on therapy.
Titrating FVIII levels needed to restore HemA mouse clots to those from wild-type mice indicated that at plasma FVIII levels around 25%,
HemA clots resemble those formed with plasma from unaffected individuals with respect to structure and biophysical properties.
However, while FVIII improved clot structure and properties, it did not abrogate individual differences, which are still detectable in the fibrin meshwork and rheology changes.
Our findings not only addressed the fundamental question regarding how clots formed by individuals with HemA differed from those formed by unaffected individuals, but also provided insights into the clot characteristics that might need to be achieved at optimum FVIII trough levels (5-25% in our study).
| MATERIALS AND METHODS

| Clot time (CT), fibrinogen and clot structure in HemA plasma
Kinetics of turbidity development during activated partial throm- Bedford, MA, USA), using on-board ACL TOP tests. HemA and control clots were prepared using similar conditions as the aPTT assay using HemA and pooled plasma from healthy donors (HRF, Inc), respectively. CT was determined from the second derivative of the turbidity change over time, and turbidity waveform data were extracted from the ACL TOP using proprietary software developed by Bayer Business Services (Leverkusen, Germany). Changes in turbidity parameters were correlated with changes in CTs and with fibrinogen levels.
Direct visualization of plasma clots was achieved by confocal microscopy of plasma. HemA plasma clots were prepared as described above for turbidity assessment, except that Alexa 488-labeled fibrinogen (Invitrogen, Carlsbad, CA, USA) was added to the plasma before clot formation. Three-dimensional image data sets of clots were collected with a Zeiss LSM510 confocal microscope (Zeiss, Oberkochen,
Germany). Reconstructions of 60 z-sections were computed.
| Clot mechanical properties in HemA patient whole blood by rheometry
Whole blood (10 mL) was collected in acid-citrate-dextrose from adults with severe HemA (FVIII <1%). Patients in the study had plasma FVIII <1%, without detectable FVIII inhibitors (<0.6 Bethesda units, Table S1 ). The protocol was approved by the University of
Essentials
• Factor VIII (FVIII) replacement in hemophilia A corrects bleeding due to low thrombin generation.
• There is uncertainty about the minimal or trough level of FVIII needed for optimal treatment.
• FVIII improves physical properties of hemophilia clots, including stiffness and permeability.
• Fibrinogen and blood cells also stabilize hemophilia clots to decrease bleeding risk.
Pennsylvania Institutional Review Board, and all patients signed informed consent. 
| Composition of wound clots from HemA mice treated with rFVIII
This study utilized the saphenous vein model, which had been used previously to measure the bleeding times in HemA mice. [12] [13] [14] In these studies, untreated HemA mice did not form clots within 15 minutes.
However, HemA mice with 5% FVIII formed small, fragile but visible clots and served as reference controls.
HemA mice (n=5/treatment) were given FVIII prior to puncture to achieve plasma levels of 5%, 25%, and 100% at 15 minutes after dosing when injury occurred. Saphenous veins were punctured with a 23-gauge needle, and the time required for cessation of bleeding was designated as primary CT. Some of these primary clots were examined as controls for determination of the structure and composition of normal clots. For the HemA mice, the nascent primary clot was disrupted again with a 23-gauge blunt needle, and the time required for cessation of re-bleeding was designated the secondary CT. The saphenous vein segment containing the wound was carefully separated from the rest of the tissues and excised, with the wound clot retained in the smaller, more distal segment of the vessel, so that the environment and orientation of each clot could be observed. Saphenous veins containing primary and secondary clots from excipient-treated, unaffected mice (n=5 each) were similarly generated and harvested.
The isolated saphenous vein segments were washed, fixed, and processed as described. 15 Quantitative assessment of clot composition was carried out by previously used procedures that allow the determination of the relative volume of different components from the micrographs. 16 On a computer monitor, a fine grid (1.5 μm × 1.5 μm) was overlaid on each scanning electron microscope image using ImageJ (v1.48, National Institutes of Health, Bethesda, MD, USA), such that there was usually only 1 structure present in each grid square, and the structures in each image were quantified. 16 
| Statistical analysis
Differences between groups were tested using analysis of variance (ANOVA), with Dunnett correction for multiple comparisons and unpaired Student t test. Analyses were performed using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA, USA). ). The effect of FVIII on individual HemA plasma CT and maximal turbidity are shown in Figure 1D .
| RESULTS
| Individual variation in
FVIII decreased both CT and maximal turbidity, which reflects the thickness of fibrin fibers within a fibrin meshwork. 17 Interestingly, despite restoration of HemA CT to near normal with 25% FVIII, HemA plasma clots from different donors exhibited divergent fibrin fiber diameters,
as assessed by maximum turbidity values. The variation in fibrin fiber diameters, however, is directly correlated with individual plasma fibrinogen levels ( Figure 1B ), indicating that clot structure (specifically average fibrin fiber cross-sectional area) is sensitive to both fibrinogen levels and thrombin generated during coagulation, 15 and hence, perhaps, a better clinical indicator than CT. Furthermore, these results raise the possibility that increasing HemA patient plasma FVIII levels to 25% with replacement therapy may uniformly achieve near-normal CT, without producing fibrin clots with the same network structure in all HemA patients.
The results of Figure 1D suggest that variation in HemA patient plasma fibrinogen may partially account for the heterogeneity of clot structure as assessed indirectly by turbidity.
| Individual variation in turbidity also corresponds to individual changes in clot structure
Confocal microscopy of FVIII-spiked plasma clots from individual donors also demonstrated considerable individual variation in fibrin structure, despite their dose-dependent response to FVIII (Figure 2 and Fig. S2 ).
FVIII increased fiber density, and the plasma clots consisted of thinner, more highly branched fibers, resulting in smaller pore sizes ( Figure 2 ).
Interestingly, although all plasma clots showed similar FVIII-dependent changes, individual differences in clot structures were still evident, particularly with respect to meshwork density and apparent fiber diameter. This may be related to the difference in fibrinogen content in plasma ( Figure 1D and B), although the magnitude of the fibrinogen level difference had small effects in characteristics of in vitro clots formed with purified fibrinogen. F I G U R E 2 Effect of FVIII on HemA plasma clot structure. Changes in individual HemA plasma clot structure with the indicated FVIII supplementation were visualized by confocal microscopy as described in the Methods. Levels of FVIII depicted were chosen to capture potential clot structures formed in severe (0%) and mild (5% and 25%) HemA. Effects of other FVIII levels reflective of the continuum of HemA disease severity can be further visualized in Fig. S2 . rFVIII, recombinant FVIII 0% rFVIII 5% 25%
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Because the HemA whole blood was derived from HemA patients with known clinical histories (Table S1) , we attempted to correlate individual Gʹ results with bleeding phenotype. However, we were unable to assess the relationship between their bleeding history and rheology because all five HemA patients had histories of recurrent hemarthrosis, and the number of participants in the study was small and their treatments were variable.
In contrast to Gʹ, clot plasticity Gʹʹ changes were considerably smaller, increasing from a baseline of ~4 to 8 Pa to ~12 Pa with 100%
FVIII supplementation ( Figure 3B ). Unlike Gʹ, Gʹʹ showed less FVIIIdependent increase, suggesting that Gʹ may be a more responsive parameter to FVIII replacement.
To better assess the relationship between bleeding, FVIII levels, and alterations in clot structure and properties in vivo, we assessed the effect of FVIII dosage on wound clots of HemA mice subjected to saphenous vein puncture. The saphenous vein is a commonly used hemostasis model owing to ease of access and histological preparation and because
HemA mice do not spontaneously develop joint arthropathy.
| Effect of FVIII replacement on HemA wound clot structure and composition
HemA mice (n = 5/condition) were subjected to injury by puncture of the saphenous vein, as described previously. [12] [13] [14] In this model, the initial clot was disturbed for observation of the secondary (rFVIII-dependent) bleeding times and clot structure, ( Figure 4A ). Bleeding times in the HemA mice were greatly prolonged, but reduced by rFVIII ( Figure 4B ).
Despite the limitation of scanning electron microscopy, which allows visualization of exposed surfaces, details of the disrupted clot structure displayed areas with both fibrin and platelets ( Figure 5A , D, E, and F; Figure 6B , D, and F). As in contracted clots in vitro, there were areas containing a dense meshwork of fibrin and/or platelets on the surface ( Figure 5A , E, and F; Figure 6B) , and, when visible, interior structures consisted mostly of polyhedrocytes (polyhedral erythrocytes) ( Figure 5B-D; Figure 6C and H). There were also erythrocyte structures that were recognized from other studies 11, 19 as forms Figures 5D and 6D ).
In addition, there were erythrocytes that were balloon-like, attached by a single point to pores in the fibrin mesh (Figure 5E and F; Figure 6G ).
Comparison of the clots generated under different conditions demonstrated striking differences in the appearance of clots from
HemA mice with low (5%) plasma FVIII compared with control clots from unaffected mice. The major components of control clots were erythrocytes and fibrin, as expected for venous clots, although unexpectedly most of the erythrocytes were polyhedral in shape (polyhedrocytes). 11 In contrast, in the clots from HemA mice with 5%
FVIII, fibrin and erythrocytes formed a much smaller proportion, and platelets formed a disproportionately larger fraction of the total wound clot. It should also be noted that even in the HemA mice, nearly all erythrocytes present in these clots were polyhedrocytes or intermediate, between discoid and polyhedral in form, and only a very small proportion of typical biconcave discoid erythrocytes were present with no statistical difference between the treatment groups (P > 0.05).
Unlike clots formed in vitro, 11 these ex vivo clots were highly heterogeneous. Some areas were rich in platelets and microparticles (Figure 5A and E; Figure 6A , B, and E), and others were mostly fibrin ( Figure 6B and I). Nevertheless, there were clear differences between clots from HemA mice with lower FVIII versus higher FVIII or controls. Relative to 
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unaffected control clots, platelet-rich areas were more common, and fibrin-rich areas were less common in HemA clots by general inspection.
Quantification of clot composition was carried out by accurate and robust methods as previously described, accounting for all structures observed. 16 In control clots, we found that in the 18 348 structures quantified, polyhedrocytes (29.6±2.5%) and intermediate forms (13.0±3.8%) (identified from other studies 11, 19 ) of compressed erythrocytes were a major component of these clots, altogether making up about 44.9%
of the volume, with only 1.7±0.7% biconcave erythrocytes (Table S2 ).
Other components were fibrin (40.1±7.7%), platelets (9.7±3.0%), microparticles (4.4±1.3%) and leukocytes (0.4±0.1%). Clots commonly contained closely packed polyhedrocytes surrounded by fibrin and platelets, as observed in contracted clots in vitro. An important conclusion of these studies is that polyhedrocytes comprise a large fraction of the mass of venous clots and are not merely an in vitro phenomenon or experimental artifact, and that there is segregation of much of the fibrin and platelets to the exterior of the contracted clot and polyhedrocytes on the interior.
In clots from HemA mice, >46 000 structures from four conditions were analyzed. Because clots were very small and sizes varied for each mouse, averages for each condition were normalized by the total number of structures in that particular clot to minimize the impact of outliers. These results confirmed and quantified the visual impressions mentioned above: fibrin is the major component (40%) of the unaffected control clots and HemA clots with a higher level (25% and 100%) of FVIII ( Fig. S3 and Table S2 ). In contrast, HemA clots with low (5%) FVIII contained a high (37%) percentage of platelets in comparison with HemA clots with higher FVIII (or unaffected controls, 12%). Likewise, the microparticle content reflected the platelet composition. These differences were statistically significant.
In addition to having less fibrin and a higher proportion of platelets and microparticles, the distribution of erythrocyte forms varied in HemA clots with low versus higher FVIII. Polyhedrocytes formed a lower percentage (15%) of the clot in the presence of low FVIII (HemA with 5%) relative to the 30% found in clots from mice with higher FVIII. Moreover, biconcave normal erythrocytes constituted 3% of total in HemA mice with 5% FVIII versus the ~1.5% found in mice with higher FVIII levels. Surprisingly, the proportion of intermediate-form red blood cells for all groups was about the same (Table S2 ).
To compare clots with different levels of FVIII, normalization is needed to account for differences in clot size while clot composition is changing. For example, without normalization, it appears that as FVIII (and consequently thrombin) increased, the percentage of platelet aggregates decreased, which seems unlikely. With increasing FVIII (thrombin), fibrin is most likely to increase while platelet aggregates should remain either constant or perhaps increase. Because the simplest assumption is that the percentages of platelet aggregates are relatively constant, we chose to normalize other components with respect to platelet aggregate content. Comparison of the normalized clot composition of HemA mice with 5% plasma FVIII versus mice containing higher plasma levels of FVIII (HemA with 25% and 100% FVIII or unaffected control mice) affirmed significant differences in predominant components: fibrin, polyhedrocytes, and polyhedrocytes combined with intermediate-shaped red blood cells (Figure 7 ). However, in comparison with unaffected control clots, HemA clots containing higher FVIII levels (25% and 100%)
showed nearly identical percentages of all components, indicating that infusion of even 25% FVIII effectively corrects the clot structure in the HemA mice. There were no significant differences between the unaffected group versus HemA mice with higher FVIII levels.
| DISCUSSION
Investigation of human HemA clotting by turbidity and confocal microscopy revealed effects on clotting rates and clot structures consistent with expectations from the reduced thrombin levels, but the effects on viscoelastic properties of the clots are more striking than effects measured by other methods. For example, by thromboelastography, it was difficult to discern differences between severe and moderate hemophilia. 20 On the other hand, by rheometry, the differences between
HemA whole blood supplemented with 1% versus 5% were clearly discernible. While we were unable to study wound clots from HemA mice with plasma FVIII levels <5% because our focus on re-bleeding requires the formation of a discernible clot, our results suggest that methods more specific for clot structure and physical properties might provide more information. The differences between mouse HemA venous clots with different levels of FVIII and controls were striking and novel using scanning electron microscopy to assess whole blood clots. Our studies clearly demonstrated that plasma levels of ~25% and higher FVIII were sufficient to convert HemA clots toward unaffected clots, with respect to clot structure, rheology, and CTs. These results are consistent with recent findings that trough levels at ~15% FVIII may be adequate to prevent bleeding. 6 However, the observation that mild HemA patients with plasma levels between 5% and 40% have reduced range of motion, 21 suggestive of subclinical joint bleeding, indicates that plasma levels at 15% or higher do not necessarily equate to no bleeding risk.
Although further increases in FVIII could decrease HemA CT to the same level as unaffected controls ( Figure 1D ), the variations observed in fibrinogen levels ( Figure 1B) , fibrin fiber diameters, fiber branching, and the ability to form an interconnected meshwork and attain specific viscoelastic properties predict that the ability of HemA clots to stop bleeding may depend on more than circulating FVIII levels. For example, for plasma 831, the fibrin meshwork attained with 5% FVIII supplementation was comparable to that attained with higher FVIII supplementation ( Figure 2 ). Not surprisingly, plasma 831 was one of the two plasmas tested that contained similar fibrinogen levels as normal pool ( Figure 1B and D) and achieved closer maximal turbidity values approximating pooled normal plasma. In addition, different levels of FVIII are required to achieve a specific change in clot stiffness. For example, for some donors (S2 and S3), only 25% FVIII was required, while other donors (S1 and S5) required considerably more FVIII ( Figure 3A ).
Variations in HemA patient hemostatic response could reflect differences in plasma coagulation factors and cellular elements, including fibrinogen, that affect clot turbidity and fibrin polymerization characteristics, 15 and ultimately clot structure and viscoelastic properties. In our studies, supplementation of individual plasma to the same level of FVIII still revealed individual differences in fibrin meshwork and clot stiffness ( Figures 1D and 3A ).
Other sources of individual variation in HemA response can include the formed elements of blood, specifically platelets and erythrocytes. Platelets have a positive effect on clot organization and resistance to lysis, 22 and erythrocytes modulate the organization and rheology of clots. 
